MONTREAL, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company’s President and CEO, Paul Lévesque will be presenting at two investor conferences in September. Members of the Theratechnologies management team will also be available for one-on-one meetings throughout the conferences.
| H.C. Wainwright 26th Annual Global Investment Conference | |
| Date: | September 9-11, 2024 |
| Location: | Lotte New York Palace Hotel |
| Presentation Details: | Virtual presentation accessible online to conference attendees on the morning of Monday, September 9, 2024 |
| 2024 Cantor Global Healthcare Conference | |
| Date: | September 17-19, 2024 |
| Location: | InterContinental Barclay Hotel, New York |
| Presentation Details: | Fireside chat on Wednesday, September 18 at 8:00-8:30 a.m. ET in Track 4, Empire Ballroom 1 |
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on LinkedIn and X (formerly Twitter).
Contacts:
Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-438-315-6608
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-514-336-7800
| Last Trade: | US$3.25 |
| Daily Change: | 0.01 0.31 |
| Daily Volume: | 973,450 |
| Market Cap: | US$149.440M |
July 02, 2025 April 09, 2025 April 08, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
